Explore the Mechanism of Action

ORZEYFUL targets the underlying orexin deficiency associated with NT1 by activating orexin receptor 21

By activating the same brain receptor normally stimulated by the body's own orexin,

ORZEYFUL helps restore the missing orexin signal in NT12,3

Neuronal synapse with ORZEYFUL

ORZEYFUL is designed to activate orexin receptor 2 to restore orexin signaling1,3

For illustrative purposes only. This figure is intended only to show oveporexton binding to orexin receptors to demonstrate receptor engagement.

A support representative with a briefcase icon

Connect with us

Get resources and information about ORZEYFUL or request to speak with a Takeda representative

REM=rapid eye movement.

References: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals. 2. FDA approves first drug to treat the full range of narcolepsy type 1 symptoms. News release. US Food and Drug Administration. August 5, 2026. Accessed August 13, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms 3. Mitsukawa K, Terada M, Yamada R, et al. TAK-861, a potent, orally available orexin receptor 2–selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Sci Rep. 2024;14(1):20838. doi:10.1038/s41598-024-70594-1